Diabetes Remote Intervention to improVe Use of Evidence-based Medications
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT06046560
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT06046560
-
- Main results
- Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial
- Other papers using this trial's data
- Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06046560. Randomized; no masking; primary purpose prevention. Start 2021-03-22 (actual); primary completion 2023-07-25 (actual). Results posted on 2024-10-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Diabetes Remote Intervention to improVe Use of Evidence-based Medications
- Acronym
- DRIVE
- Condition
- Cardiovascular Diseases
- Condition
- Diabetes
- Intervention (Drug)
- SGLT2 inhibitor, GLP-1 RA
- Intervention (Behavioral)
- Education-First
- Lead sponsor
- Brigham and Women's Hospital
- Collaborator
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06046560- Content hash
aa2ee4b4c844fdc8f93da9b1479537fe119e5acb586d517e9700c75b1a6c4316